<DOC>
	<DOCNO>NCT02950259</DOCNO>
	<brief_summary>The goal study assess safety tolerability IRX-2 regimen patient early stage breast cancer ( ESBC ) .</brief_summary>
	<brief_title>Pre-operative IRX-2 Early Stage Breast Cancer ( ESBC )</brief_title>
	<detailed_description>This Phase Ib study conduct determine safety tolerability IRX-2 regimen ESBC , administer pre-operatively standard-of-care surgical resection follow standard-of-care diagnostic biopsy . Eligible subject early stage breast cancer receptor subtype , standard-of-care surgical resection plan . To eligible , minimum 1 core tumor-bearing biopsy material must available research analysis . The IRX-2 regimen administer enrolled subject . IRX 2 administer subcutaneous injection periareolar skin affect breast .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Invasive breast cancer receptor subtype diagnose coreneedle biopsy To undergo surgical resection curative intent partial mastectomy ( lumpectomy ) mastectomy Tumor &gt; 5 mm maximum diameter ultrasound mammography . ( Subjects small tumor may include discretion Principal Investigator . ) Willing able provide write informed consent , include consent use available tissue require blood draw research purpose Availability least one tumorbearing core specimen breast cancer diagnostic biopsy Karnofsky Performance status ( KPS ) 70 % great . Female male â‰¥18 year age day sign informed consent . Adequate organ function define protocol specify lab result Prior neoadjuvant systemic therapy plan Prior surgery , radiotherapy chemotherapy cancer ( coreneedle biopsy ) Received investigational agent within 4 week first dose treatment . Diagnosis immunodeficiency receive replacement dos corticosteroid immunosuppressive therapy within 4 week first dose treatment Hypersensitivity IRX 2 , cyclophosphamide , indomethacin , aspirin ciprofloxacin . Chronic anticoagulation , include aspirin , include heparin , warfarin , oral anticoagulant platelet function inhibitor , , documented opinion investigator , safely interrupt least 2 day prior initiation study regimen surgical resection tumor . Another malignancy require active treatment within 6 month first dose treatment History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , trial participation best interest subject , include limited uncontrolled hypertension clinically significant cardiovascular disease , myocardial infarction within previous 3 month , active infection pneumonitis pulmonary disease require systemic therapy , clinically significant gastritis peptic ulcer disease ( would preclude use indomethacin ) , stroke symptoms cerebral vascular insufficient within last 3 month , autoimmune disease require systemic treatment within past 2 year ( hormone replacement dos ) , uncontrolled psychiatric substance abuse disorder . Pregnancy lactation . Known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) , active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Early Stage Breast Cancer</keyword>
	<keyword>Male breast cancer</keyword>
	<keyword>IRX-2</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>